Descripción del proyecto
Un diagnóstico rápido innovador para las enfermedades infecciosas farmacorresistentes
Las infecciones resistentes a los antimicrobianos figurarán entre las principales causas de muerte en todo el mundo en 2050. La tuberculosis multirresistente (TB-MDR) provoca cada año más de 240 000 muertes en todo el mundo (de las que 10 000 se dan en Europa), muchas de las cuales se deben a la incapacidad de detectar la resistencia y la sensibilidad a los antibióticos en el proceso de diagnóstico. El proyecto Tuberculini, financiado con fondos europeos, evaluará la viabilidad técnica y comercial de una plataforma única que diagnostica de forma rápida enfermedades infecciosas farmacorresistentes, como la TB-MDR, y proporciona un plan terapéutico adecuado. La plataforma utiliza cebadores patentados para amplificar el ADN específico de las muestras de los pacientes, seguido de un análisis de secuenciación de nueva generación (SNG) y algoritmos de aprendizaje automático para comentar los datos de la SNG y determinar la sensibilidad o resistencia en función de perfiles de ADN.
Objetivo
Company: Clemedi AG is a Swiss SME, founded in 2019 as a spin-off from the University of Zurich, with the aim to develop in vitro diagnostic (IVD) tests for antibiotic resistance and susceptibility in infectious diseases. The vision of Clemedi is to support the global battle against antibiotic resistance by developing IVDs that will allow personalized prescription of antibiotics.
Need to address: Antimicrobial resistant infections will be among the world’s leading causes of death by 2050. Multi-drug-resistant tuberculosis (MDR-TB) is a large contributor to death by antimicrobial resistance, with over 240k global mortalities (of which 10k in Europe) per year. Many of these are caused by the inability to detect resistance and antibiotic susceptibility in the diagnostic process.
Solution: Clemedi is developing a unique platform to rapidly diagnose drug-resistant infectious diseases, including MDR-TB, and rapidly provide a matching therapy plan. The platform uses proprietary primers to amplify specific DNA from patient samples, followed by next-generation sequencing (NGS) analysis. Machine-learning algorithms are then used to annotate the NGS data, and determine susceptibility or resistance based on DNA-profiles to provide a focused advice on antibiotic therapy, within 24-48 hours after obtaining a patient’s sample.
Business opportunity: The minimum total addressable market for Clemedi (i.e. every person that needs to be diagnosed for MDR-TB) is valued at €73.7 M. Competitors are companies that also develop IVDs for rapid detection of MDR-TB, such as Hain Lifescience, Cepheid and Becton-Dickinson. The main competitive advantage of Tuberculini is its ability to analyze susceptibility for a significantly larger number of antibiotics (12 vs. 1-5). Only this can positively impact disease management.
Feasibility study: Financial support from the SMEi P1 will be used to assess the technical and commercial feasibility of Tuberculini, Clemedi’s IVD for MDR-TB.
Ámbito científico
- medical and health scienceshealth sciencesinfectious diseases
- medical and health sciencesclinical medicineclinical microbiology
- medical and health sciencesclinical medicinepneumologytuberculosis
- medical and health sciencesbasic medicinepharmacology and pharmacydrug resistancemultidrug resistance
- medical and health sciencesbasic medicinepharmacology and pharmacydrug resistanceantibiotic resistance
Programa(s)
Convocatoria de propuestas
Consulte otros proyectos de esta convocatoriaConvocatoria de subcontratación
H2020-SMEInst-2018-2020-1
Régimen de financiación
SME-1 - SME instrument phase 1Coordinador
CH-8952 SCHLIEREN
Suiza
Organización definida por ella misma como pequeña y mediana empresa (pyme) en el momento de la firma del acuerdo de subvención.